Kubota Pharmaceutical Holdings Co., Ltd., a prestigious ophthalmic solutions company headquartered in Minato Ward, Tokyo, and led by Representative Director Ryo Kubota, has announced its participation in the 23rd China (Shanghai) International Optometry Fair (SIOF 2025). This significant event in the global optometry calendar will see Kubota Pharmaceutical showcasing its latest technological marvel, KUBOTA GLASS, which aims to enhance and restore vision for patients with eye diseases worldwide.

The exhibition, scheduled to take place from February 20 to 22, 2025, at the Shanghai New International Expo Center, will be open daily from 9:30 to 18:30. Kubota Pharmaceutical will be located at booth E1C73 in Hall E1. Organized by the China Optical Association and China National Light Industry International Holdings Co., Ltd., SIOF 2025 promises to attract a plethora of industry experts, corporate representatives, and professional visitors, making it an ideal platform for Kubota Pharmaceutical to showcase its innovations.

The highlight of Kubota Pharmaceutical's exhibit will be KUBOTA GLASS, an innovative glasses-type augmented reality (AR) device. This cutting-edge product simulates the visual environment of looking into the distance, effectively creating an "outdoor activity for the eyes." With the rising incidence of myopia attributed to environmental factors, particularly the decline in outdoor activities, KUBOTA GLASS utilizes advanced AR technology combined with micro-LEDs of wide wavelengths and natural light-like brightness to recreate a distant visual environment, offering a novel approach to addressing vision issues.

Kubota Pharmaceutical Holdings Co., Ltd. has consistently focused on ophthalmology, seamlessly integrating innovative ideas into the research, development, and commercialization of pharmaceuticals and medical devices. The company remains steadfast in its commitment to improving and restoring vision for patients globally. In addition to developing KUBOTA GLASS, Kubota Pharmaceutical is also active in the field of telemedicine and home healthcare, with the development of the eyeMO™ medical monitoring device, further emphasizing its dedication to bringing revolutionary advancements to eye health.

Participating in SIOF 2025 presents Kubota Pharmaceutical with a prime opportunity to demonstrate its strengths and innovative achievements, while simultaneously infusing new energy into the global eye health industry.

Introduction to Ryo Kubota

Ryo Kubota, a graduate of the esteemed Keio University School of Medicine in Japan, is a renowned ophthalmologist and medical doctor with extensive clinical experience. His surgical expertise spans various ophthalmic conditions, including glaucoma, cataracts, and retinal diseases.

During his research tenure at Keio University, Dr. Kubota achieved a significant scientific breakthrough by discovering the glaucoma-causing gene myocilin. This discovery revolutionized the pathological research and clinical treatment of glaucoma. His continued research in neurodegenerative retinal diseases has also yielded substantial results, earning him the prestigious "Suda Award," a special recognition in glaucoma research within Japanese ophthalmology, underscoring his exceptional scientific prowess and academic achievements.

In 2000, seeking broader academic horizons, Dr. Kubota moved to the United States to serve as an assistant professor at the University of Washington. Here, he continued his ophthalmic research, expanding his academic scope and deepening his professional knowledge. Two years later, in 2002, fueled by entrepreneurial aspirations and a passion for the ophthalmology industry, he embarked on his entrepreneurial journey from his basement, marking a significant milestone in his life and setting the stage for subsequent innovations in ophthalmology.